A phase I study of pazopanib in combination with escalating doses of (131)I in patients with well-differentiated thyroid carcinoma borderline refractory to radioiodine

OBJECTIVE: This trial was conducted to evaluate the ability of pazopanib to overcome therapeutic (131)I resistance. MATERIALS, METHODS AND PATIENTS: This phase 1 trial assesses the combination of pazopanib and escalating doses of radioiodine ((131)I) in patients with recurrent or metastatic thyroid...

Descripción completa

Detalles Bibliográficos
Autores principales: Chow, Laura Q., Santana-Davila, Rafael, Pantel, Austin, Roth, Mara, Anderson, Leslie N., Failor, Alan, Doot, Robert, Mankoff, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5490965/
https://www.ncbi.nlm.nih.gov/pubmed/28662033
http://dx.doi.org/10.1371/journal.pone.0178325

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5490965/
https://www.ncbi.nlm.nih.gov/pubmed/28662033
http://dx.doi.org/10.1371/journal.pone.0178325

Ejemplares similares